Poorly Differentiated Malignant Neuroendocrine Carcinoma
📧 Sign up to get email alerts when something new happens for Poorly Differentiated Malignant Neuroendocrine Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-10-28Clinical Trial Update: Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study [Phase 2]
A Phase II investigator-initiated trial evaluating safety and tolerability of everolimus as second-line therapy in poorly differentiated neu…